Proteins at the intersection of circadian rhythms and metabolic dysfunction-associated steatotic liver disease: an 18-protein panel as a novel predictive biomarker set - Takeaways - MDSpire

Proteins at the intersection of circadian rhythms and metabolic dysfunction-associated steatotic liver disease: an 18-protein panel as a novel predictive biomarker set

  • By

  • Yiyi Wang

  • Qilong Zhai

  • Xuemei Lian

  • Lei Zhao

  • May 13, 2026

Share

  • 1

    Circadian rhythm disruption is linked to the rise of metabolic disorders, particularly Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

  • 2

    Relative amplitude (RA) is a key measure of circadian rhythm disruption, showing lower values in individuals with MASLD compared to those without.

  • 3

    The study identified 18 candidate proteins as potential biomarkers for predicting RA-related MASLD, demonstrating strong predictive capabilities.

  • 4

    Machine learning models, including Random Forest and XGBoost, achieved high AUC values, indicating excellent predictive performance for RA-related MASLD.

  • 5

    An online predictive tool based on the 18-protein model has been developed to assess the risk of RA-related MASLD effectively.

Original Source(s)

Proteins at the intersection of circadian rhythms and metabolic dysfunction-associated steatotic liver disease: an 18-protein panel as a novel predictive biomarker set

  • by Yiyi Wang, Qilong Zhai, Xuemei Lian, Lei Zhao

  • May 13, 2026

Related Content

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants

Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American...

Unique Phase I NSCLC Trial Sites Decreasing in United States

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant conso...